Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02412917 · ClinicalTrials.gov registry record · Phase 3
A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia
A Phase 3 study, sponsored by ContraVir Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 237
- Enrollment target
NCT02412917: Clinical Trial Phase 3 study, sponsored by ContraVir Pharmaceuticals.
NCT02412917 is a Phase 3 study that was terminated before completion, run by ContraVir Pharmaceuticals. The registered enrollment target is 237 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (69% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02412917, a Phase 3 study, was terminated before completion, sponsored by ContraVir Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 237 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, double-blind, parallel-group, active controlled comparative study of the safety and efficacy of 2 dosing regimens of FV-100 versus valacyclovir administered for 7 days in subjects with uncomplicated AHZ(acute herpes zoster).
Primary Outcome
efficacy measure
Interventions
- DRUG valacyclovir
- DRUG FV-100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 237 participants |
| Start Date | 2015-06 |
| Est. Completion | 2017-11 |
| Phase | Phase 3 |
Why NCT02412917 stopped before completion
NCT02412917 is an interventional study that assigns participants to a tested intervention. The registered 237 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (69% lower).
The record links to 0 conditions, and to 2 interventions - of which valacyclovir is the first listed.
NCT02412917 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02412917 about?
NCT02412917 is a clinical study titled "A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia". This is a multicenter, randomized, double-blind, parallel-group, active controlled comparative study of the safety and efficacy of 2 dosing regimens of FV-100 versus valacyclovir administered for 7 days in subjects with uncomplicated AHZ(acute herpes zoster).
What is the current status of trial NCT02412917?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 237 participants. The study started on 2015-06. Estimated completion is 2017-11.
What interventions are being tested in trial NCT02412917?
The interventions under investigation include: valacyclovir (DRUG), FV-100 (DRUG).
Who is sponsoring clinical trial NCT02412917?
This trial is sponsored by ContraVir Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02412917's enrollment target sits among peer trials
237 1293rd of 2000 higher than 707 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05974176 · 237 participants · NA
Considering Racial and Acculturation Stress in Addressing Trauma
- NCT05012072 · 238 participants · NA
Reducing Pregnancy Risks: The Mastery Lifestyle Intervention
- NCT05400252 · 238 participants · NA
Whole Health in VA Mental Health: Omnis Salutis
- NCT06380517 · 238 participants · Phase 3
Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia